Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology
Toronto, Ontario / TheNewswire / November 19, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the VMS+ Software approved for all 4 chambers of the heart can be used for the analysis of 3D echo images generated by any commercially available 3D echocardiography system.
The VMS+ Software can be purchased as an important clinical tool for the successful calculation of volumetric measurements to further aid in the diagnosis of diseases and disorders of the heart. This extends our product line to a software solution that increases our footprint in the cardiac medical imaging market.
"We are looking forward to offering cardiac centres the opportunity to purchase the VMS+ Software to compliment their existing 3D echo equipment," noted Desmond Hirson, President of Ventripoint Diagnostics.
This feeds into Ventripoint's strategy to build value for our customers by providing an array of tools to improve clinical outcomes and standard of care for pediatric and adult cardiac patients.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, please contact:
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.
